For the study, published May 31, researchers from the Scripps Research Translational Institute analyzed six years of pharmacy claims data from a Blue Cross Blue Shield Axis database. The researchers focused on prescription data about 49 top-selling brand-name drugs submitted from January 2012 and December 2017. Only drugs that exceeded $500 million in U.S. sales or $1 billion in global sales were examined.
The drugs that saw the biggest price jumps, by percent change, were:
1. Viagra (190 percent)
2. Cialis (187 percent)
3. Forteo (177 percent)
4. Lexapro (150 percent)
5. Zetia (149 percent)
6. Lyrica (137 percent)
7. Lipitor (137 percent)
8. Renvela (136 percent)
9. Enbrel (133 percent)
10. Premarin (129 percent)
11. Humira (124 percent)
12. Chantix (124 percent)
13. Onfi (118 percent)
14. Novolog (118 percent)
15. Humulin (117 percent)
16. Humalog (117 percent)
17. Simponi (107 percent)
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.